Agios Pharmaceuticals, Inc. (LON:0HB0)
36.47
+0.26 (0.71%)
At close: Sep 15, 2025
Agios Pharmaceuticals Revenue
Agios Pharmaceuticals had revenue of $12.46M USD in the quarter ending June 30, 2025, with 44.57% growth. This brings the company's revenue in the last twelve months to $40.88M, up 30.57% year-over-year. In the year 2024, Agios Pharmaceuticals had annual revenue of $36.50M with 36.07% growth.
Revenue (ttm)
$40.88M
Revenue Growth
+30.57%
P/S Ratio
52.40
Revenue / Employee
$83.76K
Employees
488
Market Cap
1.56B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 36.50M | 9.68M | 36.07% |
Dec 31, 2023 | 26.82M | 12.58M | 88.36% |
Dec 31, 2022 | 14.24M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Agios Pharmaceuticals News
- 1 day ago - AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm - Business Wire
- 3 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO - PRNewsWire
- 6 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. – AGIO - GlobeNewsWire
- 8 days ago - Agios Pharmaceuticals: Why A Delayed FDA Review Could Still Be A Positive - Seeking Alpha
- 12 days ago - HC Wainwright & Co. Reiterates Buy Rating on AGIO with $56 Target | AGIO Stock News - GuruFocus
- 12 days ago - Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated - Seeking Alpha
- 12 days ago - FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use - Benzinga
- 13 days ago - Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia - GlobeNewsWire